Analysis of the contribution of immunologically-detectable HER2, steroid receptors and of the "triple-negative" tumor status to disease-free and overall survival of women with epithelial ovarian cancer

Acta Histochemica

Volumn 116, Issue 3, 2014, Pages 440-447

  De Toledo, Maria Carolina Szymanski ^a   Sarian, Luis Otavio ^a   Sallum, Luis Felipe ^a   Andrade, Liliana Lucci Angelo ^a   Vassallo, José ^a   De Paiva Silva, Geisilene Russano ^a   Pinto, Glauce Aparecida ^a   Soares, Fernando Augusto ^b   Fonseca, Camila Dal Piccolo Pracchia ^a   Derchain, Sophie F M ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b A C CAMARGO CANCER CENTER   (Brazil)

Author keywords

Androgen receptor; Estrogen receptor; HER2; Ovarian cancer; Progesterone receptor; Tissue microarray; Triple negative

Indexed keywords

ANDROGEN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; PROGESTERONE RECEPTOR; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR ALPHA, HUMAN;

ADULT; ARTICLE; BODY MASS; CANCER GRADING; CANCER STAGING; CLINICAL FEATURE; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVERALL SURVIVAL; PROPORTIONAL HAZARDS MODEL; AGED; METABOLISM; MIDDLE AGED; MORTALITY; NEOPLASM; OVARY TUMOR; PATHOLOGY;

ADULT; AGED; DISEASE-FREE SURVIVAL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; HUMANS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; RECEPTOR, ERBB-2; RECEPTORS, ANDROGEN; RECEPTORS, PROGESTERONE;

EID: 84899951186     PISSN: 00651281     EISSN: 16180372     Source Type: Journal    
DOI: 10.1016/j.acthis.2013.09.010     Document Type: Article

References (24)

1. Arias-Pulido H., Smith H.O., Joste N.E., Bocklage T., Qualls C.R., Chavez A., et al. Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors. Gynecol Oncol 2009, 114:480-485.
2. Chácon R., Constanzo M. Triple negative breast cancer. Breast Cancer Res 2010, 12:S3.
3. De Stefano I., Zannoni G.F., Prisco M.G., Fagotti A., Tortorella L., Vizzielli G., et al. Cytoplasmic expression of estrogen receptor beta (ERβ) predicts poor clinical outcome in advanced serous ovarian cancer. Gynecol Oncol 2011, 122:573-579.
4. Esfahlan R.J., Zarghami N., Esfahlan A.J., Mollazadeh M., Nejati K., Nasiri M. The possible impact of obesity on androgen, progesterone and estrogen receptors (ERα and ERβ) gene expression in breast cancer patients. Breast Cancer (Auckl) 2011, 5:227-237.
5. García-Velasco A., Mendiola C., Richardson D., Ballestín C., Colomer R., Cortés-Funes H. Prognostic value of hormonal receptors, p53, ki67 and HER2/neu expression in epithelial ovarian carcinoma. Clin Transl Oncol 2008, 10:367-371.
6. Halon A., Nowak-Markwitz E., Maciejczyk A., Pudelko M., Gansukh T., Györffy B., et al. Loss of estrogen receptor beta expression correlates with shorter overall survival and lack of clinical response to chemotherapy in ovarian cancer patients. Anticancer Res 2011, 31:711-718.
7. Hecht J., Kotsopoulos J., Hankinson S.E., Tworeger S.S. Relationship between epidemiological risk factors and hormone receptor expression in ovarian cancer: results from the Nurses' Health Study. Cancer Epidemiol Biomarkers Prev 2009, 18:1624-1632.
8. Hodgall E.V., Christensen L., Hodgall C.K., Blaakaer J., Bock J.E., Glud E., et al. Distribution of HER2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma. Cancer 2003, 98:66-73.
9. Hodgall E.V., Christensen L., Hodgall C.K., Blaakaer J., Gayther S., Jacobs I.J., et al. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the "Malova" ovarian cancer study. Oncol Rep 2007, 18:1051-1059.
10. Hoopmann M., Sachse K., Valter M.M., Becker M., Neumann R., Ortmann M., et al. Serological and immunohistochemical HER-2/neu statuses do not correlate and lack prognostic value for ovarian cancer patients. Eur J Cancer Care (Engl) 2010, 19:809-815.
11. Kommoss F., Pfisterer J., Thome M., Schafer W., Sauerbrei W., Pfleiderer A. Steroid receptors in ovarian carcinoma: immunohistochemical determination may lead to new aspects. Gynecol Oncol 1992, 47:317-322.
12. Lanitis E., Dangaj D., Hagemann I.S., Song D., Best A., Sandaltzopoulos R., et al. Primary human ovarian epithelial cancer cells broadly express HER2 at immunologically - detectable levels. PloS One 2012, 7(11):e49829. 10.1371/journal. pone.0049829.
13. Lee P., Rosen D.G., Zhu C., Silva E.G., Liu J. Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer. Gynecol Oncol 2005, 96:671-677.
14. Lenhard M., Tereza L., Heublein S., Ditsch N., Himsl I., et al. Steroid hormone receptor expression in ovarian cancer: progesterone receptor B as prognostic marker for patient survival. BMC Cancer 2012, 12:553-570.
15. Liu N., Wang X., Sheng X. The clinicopathological characteristics of 'triple-negative' epithelial ovarian cancer. J Clin Pathol 2010, 63:240-243.
16. Liu N., Wang X., Sheng X. 'Triple negative' epithelial ovarian cancer and pathologic markers for prognosis. Curr Opin Obstet Gynecol 2011, 23:19-23. [Review].
17. Motamed-Khorasani A., Jurisica I., Letarte M., Shaw P.A., Parkes R.K., Zhang X., et al. Differentially androgen-modulated genes in ovarian epithelial cells from BRCA mutation carriers and control patients predict ovarian cancer survival and disease progression. Oncogene 2007, 26:198-214.
18. Modugno F. Ovarian cancer and polymorphisms in the androgen and progesterone receptor genes: a HuGE review. Am J Epidemiol 2004, 159:319-335.
19. Nodin B., Zendehrokh N., Brändstedt J., Nilsson E., Manjer J., Brennan D.J., et al. Increased androgen receptor expression in serous carcinoma of the ovary is associated with an improved survival. J Ovarian Res 2010, 17:3-14.
20. R Core Team, 2013. R: A Language and Environment for Statistical Computing. http://www.r-project.org/.
21. Sallum L.F., Sarian L.O., Andrade L.A., Vassallo J., Soares F.A., Pinto G.A., et al. Survival of women with ovarian carcinomas and borderline tumors is not affected by estrogen and progesterone receptor status. J. Gynecol. Oncol. 2013, 24(2):167-176. [Epub 2013 Apr 5]. 10.3802/jgo.2013.24.2.167.
22. Schildkraut J.M., Bastos E., Berchuck A. Relationship between lifetime ovulatory cycles and overexpression of mutant p53 in epithelial ovarian cancer. J Natl Cancer Inst 1997, 89:932-938.
23. Yang X.Y., Xi M.R., Yang K.X., Yu H. Prognostic value of estrogen receptor and progesterone receptor status in young Chinese ovarian carcinoma patients. Gynecol Oncol 2009, 113:99-104.
24. Zhao D., Zhang F., Zhang W., He J., Zhao Y., Sun J. Prognostic role of hormone receptors in ovarian cancer. A systematic review and meta-analysis. Int J Gynecol Cancer 2013, 23:25-33.